Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK)

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A for Cytokinetics Inc. The amendment states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Cytokinetics Common Stock, representing 0% of the class as shown in the filing dated 03/13/2026 with a signature on 03/26/2026. The filing explains certain subsidiaries and business divisions will report ownership separately in reliance on SEC Release No. 34-39538.

Insights

Securities Compliance Counsel

Amendment reports zero beneficial ownership after internal realignment.

The filing states The Vanguard Group's internal realignment resulted in certain subsidiaries reporting beneficial ownership separately in reliance on SEC Release No. 34-39538. The amendment lists 0 shares and 0% beneficial ownership of Cytokinetics Common Stock as of 03/13/2026.

Legal significance is procedural: the disaggregation described is a reallocation of reporting responsibilities rather than a change in underlying custody or investment strategy, per the filing language. Subsequent filings from the named subsidiaries will show any reported holdings.

Institutional Investor Relations Analyst

Registry update clarifies reporting structure; no Vanguard stake is shown here.

The amendment clarifies that certain Vanguard subsidiaries now report separately and that The Vanguard Group no longer claims beneficial ownership of securities held by those entities. The table in the filing shows Amount beneficially owned: 0 and Percent of class: 0%.

For investors tracking ownership, relevant holdings may appear in separate 13G/A filings by Vanguard subsidiaries after the realignment; this filing itself does not indicate an economic change in Cytokinetics ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Cytokinetics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cytokinetics Inc
(b)	Address of issuer's principal executive offices: 350 Oyster Point Blvd, South San Francisco, CA, 94080
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/26/2026

FAQ

What did The Vanguard Group report for CYTK ownership in this amendment?

The Vanguard Group reported 0 shares beneficially owned of Cytokinetics Common Stock, representing 0% of the class, per the amendment filed with dates 03/13/2026 and signed 03/26/2026.

Why does the filing mention an internal realignment at Vanguard?

The filing explains Vanguard underwent an internal realignment on 01/12/2026, causing certain subsidiaries or business divisions to report ownership separately in reliance on SEC Release No. 34-39538, per the amendment's explanatory paragraph.

Does this amendment mean Vanguard sold its Cytokinetics shares?

The amendment shows Vanguard reports 0 shares for itself; it does not state whether shares were sold. The filing attributes reporting changes to disaggregation of subsidiaries rather than describing specific transactions.

Where will any Vanguard-related holdings of CYTK be reported now?

According to the amendment, holdings previously reported under The Vanguard Group may now be disclosed by specific subsidiaries or business divisions, each filing separately in reliance on SEC Release No. 34-39538.

Who signed the amendment for Vanguard and when?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/26/2026 on the filing.